Abstract:During the past several years, important advances have been made in our understanding of the mechanisms that regulate the expression of genes that determine drug clearance, including phase I and phase II drug-metabolising enzymes and drug transporters. Orphan nuclear receptors have been recognised as key mediators of drug-induced changes in both metabolism and efflux mechanisms. In this review, we summarise recent findings regarding the function of nuclear receptors in regulating drug-metabolising and transport systems, and the relevance of these receptors to clinical drug-drug interactions and the development of new drugs. Emphasis is given to two newly recognised ‘orphan’ receptors (the pregnane X receptor [PXR] and the constitutive androstane receptor [CAR]) and their regulation of cytochrome P450 enzymes, such as CYP3A4, CYP2Cs and CYP2B6; and transporters, such as P-glycoprotein (MDR1), multidrug resistance-associated proteins (MRPs) and organic anion transporter peptide 2 (OATP2). Although ‘cross-talk’ occurs between these two receptors and their target sequences, significant species differences exist between ligand-binding and activation profiles for both receptors, and PXR appears to be the predominant or ‘master’ regulator of hepatic drug disposition in humans. Several important physiological processes, such as cholesterol synthesis and bile acid metabolism, are also tightly controlled by certain ligand-activated orphan nuclear receptors (farnesoid X receptor [FXR] and liver X receptor [LXR]). In general, their ability to bind a broad range of ligands and regulate an extensive array of genes that are involved in drug clearance and disposition makes these orphan receptors attractive targets for drug development. Drugs have the capacity to alter nuclear receptor expression (modulators) and/or serve as ligands for the receptors (agonists or antagonists), and thus can have synergistic or antagonistic effects on the expression of drug-metabolising enzymes and transporters. Coadministration of drugs that are nuclear receptor agonists or antagonists can lead to severe toxicity, a loss of therapeutic efficacy or an imbalance in physiological substrates, providing a novel molecular mechanism for drug-drug interactions.

Evolution of promiscuous nuclear hormone receptors: LXR, FXR, VDR, PXR, and CAR

Nuclear Hormone Receptors PXR and CAR and Metabolic Diseases

International Union of Pharmacology. LXII. the NR1H and NR1I Receptors: Constitutive Androstane Receptor, Pregnene X Receptor, Farnesoid X Receptor Α, Farnesoid X Receptor Β, Liver X Receptor Α, Liver X Receptor Β, and Vitamin D Receptor

Nuclear Receptors PXR and CAR: Implications for Drug Metabolism Regulation, Pharmacogenomics and Beyond

Nuclear Hormone Receptors and Evolution

Regulation of Nuclear Receptors PXR and CAR by Small Molecules and Signal Crosstalk: Roles in Drug Metabolism and Beyond

Families of Nuclear Receptors in Vertebrate Models: Characteristic and Comparative Toxicological Perspective.

Evolution of pharmacologic specificity in the pregnane X receptor

Functional crosstalk of CAR-LXR and ROR-LXR in drug metabolism and lipid metabolism.

Genomewide comparison of the inducible transcriptomes of nuclear receptors CAR, PXR and PPARα in primary human hepatocytes

Nuclear Xenobiotic Receptors: Integrating Gene Regulation to Physiological Functions

Regulation of Drug-Metabolizing Enzymes by Xenobiotic Receptors: PXR and CAR

Xenobiotic Receptors Car and Pxr

Chapter 3 Nuclear Xenobiotic Receptors

Evolution of Minimal Specificity and Promiscuity in Steroid Hormone Receptors

Xenobiotic-sensing nuclear receptors involved in drug metabolism: a structural perspective

Role of Orphan Nuclear Receptors in the Regulation of Drug-Metabolising Enzymes

Nuclear receptors as targets for drug development: regulation of cholesterol and bile acid metabolism by nuclear receptors

Advances in the Research of Pregnane X Receptor and Constitutive Androstane Receptor

Evolution of vertebrate steroid receptors from an ancestral estrogen receptor by ligand exploitation and serial genome expansions

The Emerging Role of Constitutive Androstane Receptor and Its Cross Talk with Liver X Receptors and Peroxisome Proliferator-Activated Receptor A in Lipid Metabolism.